Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to examine the safety and tolerability, pharmacokinetics of FE
202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood
vessel) leakage. FE 202158 had previously been tested in healthy volunteers.